World News

Chronic hepatitis B affects an estimated 3.2 million people in Europe alone and more than 250 million people globally.

Avlayah’s approval validates Denali’s blood-brain barrier shuttle technology, which the company now applies across five clinical programs targeting Alzheimer’s disease, Parkinson’s disease, and Sanfilippo syndrome type A, among others.

The initiative directly addresses a fundamental challenge: making scientific careers more attractive while simultaneously creating pathways for professional advancement.

The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.

Gilead will pay USD1.68 billion upfront and commit up to USD500 million in milestone payments to secure gamgertamig (OM336), Ouro’s BCMA/CD3-targeting TCE.

The 460,000-square-foot factory will sit on a 79-acre plot within the Rowen innovation district, near Dacula, Georgia, approximately 35 miles northeast of downtown Atlanta.

This building will accommodate up to 250 researchers and provides a collaborative workspace with modular laboratories designed to support both growth and interdisciplinary exchange.

Construction is expected to be complete by the third quarter of 2027, at which point the site’s workforce is also set to double.

The national rollout of Universal Health Insurance now reaches more communities, while digital transformation accelerates with GoTHOMIS installation reaching 97.8% across public facilities.

Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.